In this work, we developed lysine-free recombinant EGF mutants, where two intrinsic lysine residues were replaced with either serine (S) or arginine (R), to improve anti-cancer effects of EGF-GNPs conjugates by controlling the orientation of EGF against nanoparticle surface. This evidence concerns the gene EGF and cancer.